{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T07:02:49Z","timestamp":1777878169174,"version":"3.51.4"},"reference-count":51,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Hematology"],"published-print":{"date-parts":[[2016,8]]},"abstract":"<jats:p>Lenalidomide, an immunomodulatory drug that the US Food and Drug Administration (FDA) approved for the treatment of multiple myeloma, 5q- myelodysplasia and mantle-cell lymphoma (MCL), has encouraging efficacy in other B-cell malignancies. Its unique mechanism of action is in part due to altering the tumor microenvironment and potentiating the activity of T and natural-killer (NK) cells. Impressive clinical activity and excellent tolerability allows broad applicability. Lenalidomide has been used in a wide range of B-cell malignancies for years, but in 2013, the FDA marked its approval as a single agent only in relapsed\/refractory mantle-cell lymphoma. Perhaps most impressive is the efficacy of lenalidomide when combined with monoclonal antibodies. Impressive efficacy and toxicity profiles with the combination of lenalidomide and rituximab in B-cell lymphomas in both the upfront and relapsed\/refractory setting may allow a shift in our current treatment paradigm in both indolent and aggressive non-Hodgkin lymphoma (NHL). This review will summarize the current data in the relapsed\/refractory and front-line setting of NHL with single-agent lenalidomide as well as its use in combination with other agents.<\/jats:p>","DOI":"10.1177\/2040620716652861","type":"journal-article","created":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T22:34:13Z","timestamp":1467412453000},"page":"209-221","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":30,"title":["A comprehensive review of lenalidomide in B-cell non-Hodgkin lymphoma"],"prefix":"10.1177","volume":"7","author":[{"given":"Mili","family":"Arora","sequence":"first","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, NC, USA Department of Veterans\u2019 Affairs, Northern Carolina Healthcare System, NC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonia","family":"Gowda","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, NC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Tuscano","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, Department of Veterans\u2019 Affairs, Northern Carolina Healthcare System, UC Davis Medical Center4501 X StreetSacramento, CA 95817, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2016,7,1]]},"reference":[{"key":"bibr1-2040620716652861","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28405"},{"key":"bibr2-2040620716652861","volume-title":"The 13th International Conference on Malignant Lymphoma","author":"Albertsson-Lindblad A.","year":"2015"},{"key":"bibr3-2040620716652861","doi-asserted-by":"publisher","DOI":"10.1038\/35000501"},{"key":"bibr4-2040620716652861","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19980201)82:3<567::AID-CNCR20>3.0.CO;2-Z"},{"key":"bibr5-2040620716652861","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.5367"},{"key":"bibr6-2040620716652861","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V124.21.4476.4476"},{"key":"bibr7-2040620716652861","first-page":"1927","volume":"92","author":"Coiffier B.","year":"1998","journal-title":"Blood"},{"key":"bibr8-2040620716652861","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2008.26.15_suppl.7079"},{"key":"bibr9-2040620716652861","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-2381"},{"key":"bibr10-2040620716652861","volume-title":"56TH ASH Annual meeting and exposition","author":"Eva Kimby","year":"2014"},{"key":"bibr11-2040620716652861","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V124.21.3100.3100"},{"key":"bibr12-2040620716652861","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V120.21.2748.2748"},{"key":"bibr13-2040620716652861","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70455-3"},{"key":"bibr14-2040620716652861","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12708"},{"key":"bibr15-2040620716652861","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-03-147025"},{"key":"bibr16-2040620716652861","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V124.21.1754.1754"},{"key":"bibr17-2040620716652861","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.49.2835"},{"key":"bibr18-2040620716652861","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.5363"},{"key":"bibr19-2040620716652861","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07626.x"},{"key":"bibr20-2040620716652861","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-013-1751-z"},{"key":"bibr21-2040620716652861","doi-asserted-by":"publisher","DOI":"10.1126\/science.1177319"},{"key":"bibr22-2040620716652861","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.22.3214"},{"key":"bibr23-2040620716652861","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V124.21.799.799"},{"key":"bibr24-2040620716652861","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-2-36"},{"key":"bibr25-2040620716652861","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-01-625004"},{"key":"bibr26-2040620716652861","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.9258"},{"key":"bibr27-2040620716652861","volume-title":"56th ASH Annual Meeting and Exposition","author":"Li X.","year":"2014"},{"key":"bibr28-2040620716652861","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.119"},{"key":"bibr29-2040620716652861","unstructured":"Lymphoma Research Foundation. (2016) Follicular lymphoma. Available at: http:\/\/www.lymphoma.org. Accessed 21 April 2016."},{"key":"bibr30-2040620716652861","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2014.32.15_suppl.8521"},{"key":"bibr31-2040620716652861","volume-title":"11th International Conference on Malignant Lymphoma","author":"Morrison V.","year":"2011"},{"key":"bibr32-2040620716652861","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.55.5714"},{"key":"bibr33-2040620716652861","volume-title":"15th Congress of the European Hematology Association","author":"Puccini B.","year":"2010"},{"key":"bibr34-2040620716652861","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-04-217687"},{"key":"bibr35-2040620716652861","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa012914"},{"key":"bibr36-2040620716652861","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505237"},{"key":"bibr37-2040620716652861","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60605-9"},{"key":"bibr38-2040620716652861","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V83.5.1165.1165"},{"key":"bibr39-2040620716652861","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V124.21.3091.3091"},{"key":"bibr40-2040620716652861","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2012.30.15_suppl.8075"},{"key":"bibr41-2040620716652861","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-13-0750"},{"key":"bibr42-2040620716652861","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.172"},{"key":"bibr43-2040620716652861","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12755"},{"key":"bibr44-2040620716652861","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70191-3"},{"key":"bibr45-2040620716652861","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.95"},{"key":"bibr46-2040620716652861","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.11.4483.bloodjournal87114483"},{"key":"bibr47-2040620716652861","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq626"},{"key":"bibr48-2040620716652861","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.1169"},{"key":"bibr49-2040620716652861","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2012.05.024"},{"key":"bibr50-2040620716652861","volume-title":"13th International Conference on Malignant Lymphoma: 56th ASH Annual Meeting and Exposition","author":"Zaja F.","year":"2015"},{"key":"bibr51-2040620716652861","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2011.051813"}],"container-title":["Therapeutic Advances in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2040620716652861","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/2040620716652861","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2040620716652861","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:13:40Z","timestamp":1777590820000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/2040620716652861"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,1]]},"references-count":51,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["10.1177\/2040620716652861"],"URL":"https:\/\/doi.org\/10.1177\/2040620716652861","relation":{},"ISSN":["2040-6207","2040-6215"],"issn-type":[{"value":"2040-6207","type":"print"},{"value":"2040-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,1]]}}}